<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2277">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00229333</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-03-3124-AS-CTIL</org_study_id>
    <nct_id>NCT00229333</nct_id>
  </id_info>
  <brief_title>Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer's Disease, Vascular Dementia, and Mixed Vascular and Alzheimer's Dementia</brief_title>
  <official_title>Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer's Disease, Vascular Dementia and Mixed Vascular and Alzheimer's Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheba Medical Center</source>
  <brief_summary>
    <textblock>
      The goal of the present study is to compare the effectiveness of the active (S)-enantiomer of&#xD;
      citalopram, escitalopram with placebo in the treatment of patients with depressive syndrome&#xD;
      complicating Alzheimer's dementia (AD), vascular dementia (VD) or mixed dementia (MD), for 8&#xD;
      weeks of double-blind treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2004</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cornell Scale for Depression in Dementia (CSDD) total score</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohen-Mansfield Agitation Inventory (CMAI; Cohen-Mansfield et al. 1989)</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Depressive Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject meets criteria for the diagnosis of Alzheimer's dementia, or vascular&#xD;
             dementia, or mixed alzheimer's and vascular dementia, according to Diagnostic and&#xD;
             Statistical for Mental Disorders, Fourth Edition (DSM-IV) criteria.&#xD;
&#xD;
          -  Subject meets the following criteria for depressive syndrome: DSM-IV criteria for&#xD;
             major depressive episode; and Cornell Scale of Depression in Dementia is 18 or more.&#xD;
&#xD;
          -  The depressive syndrome has been present for at least two weeks preceding study entry&#xD;
             (Visit 1).&#xD;
&#xD;
          -  The depressive syndrome must be at least moderate in severity at Visit 1 and Visit 2&#xD;
             (cause the subject impairment in functional capacity) and in the opinion of the&#xD;
             investigator require pharmacological intervention.&#xD;
&#xD;
          -  Score on the Mini Mental State Examination (MMSE) of 10-26 at Visit 1 and at Visit 2.&#xD;
&#xD;
          -  Other possible reasons for the subject's depressive symptoms, for example, medications&#xD;
             or other medical conditions (such as pain, infection, cancer of the pancreas, etc.),&#xD;
             have been excluded as an etiology.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who need placebo run-in period, and/or their caregivers are unable to comply&#xD;
             with Study Period I medication to the extent that drug compliance in the remainder of&#xD;
             the study would be compromised as determined by the investigator.&#xD;
&#xD;
          -  Investigators, site personnel directly affiliated with this study, and their immediate&#xD;
             families. Immediate family is defined as a spouse, parent, child or sibling, whether&#xD;
             biological or legally adopted.&#xD;
&#xD;
        Diagnostic Exclusion Criteria:&#xD;
&#xD;
          -  Schizophrenia&#xD;
&#xD;
          -  Subjects who are judged clinically to be at serious suicidal risk at Visit 1.&#xD;
&#xD;
          -  Subjects who have clinically significant psychotic symptoms at Visit 1.&#xD;
&#xD;
          -  Subject has a serious neurological condition other than AD, VD or MD including, but&#xD;
             not limited to: traumatic (head-brain) dementia, space-occupying lesion, relevant&#xD;
             structural abnormalities on brain imaging, etc.&#xD;
&#xD;
          -  Subject who underwent CVA for 3 months.&#xD;
&#xD;
          -  Subject is doing well on a current antidepressant drug regimen.&#xD;
&#xD;
        Exclusionary Concurrent or Historical Illness:&#xD;
&#xD;
          -  Subjects with severe hepatic or renal insufficiency.&#xD;
&#xD;
          -  Hypo/hyperthyroidism&#xD;
&#xD;
          -  B-12 deficiency&#xD;
&#xD;
        Exclusionary Concomitant or Historical Medications:&#xD;
&#xD;
          -  Participation in a clinical trial of another investigational drug within 30 days prior&#xD;
             to study entry (Visit 1) and/or any concurrent investigational study.&#xD;
&#xD;
          -  Subjects with a history of severe adverse reaction to citalopram or escitalopram.&#xD;
&#xD;
          -  Concomitant medication as specified.&#xD;
&#xD;
          -  Previous treatment with escitalopram unless, in the opinion of the investigator, the&#xD;
             patient's previous treatment was inadequate in dose and/or duration to provide an&#xD;
             accurate assessment of the therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Sverdlik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Sverdlik, MD</last_name>
    <phone>972-54-4718424</phone>
    <email>annasver@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Sverdlik, MD</last_name>
      <phone>972-54-4718424</phone>
      <email>annasver@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Aviva Cohen, BA</last_name>
      <phone>972-3-5305910</phone>
    </contact_backup>
    <investigator>
      <last_name>Anna Sverdlik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2006</verification_date>
  <study_first_submitted>September 27, 2005</study_first_submitted>
  <study_first_submitted_qc>September 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2005</study_first_posted>
  <last_update_submitted>August 28, 2006</last_update_submitted>
  <last_update_submitted_qc>August 28, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2006</last_update_posted>
  <keyword>Escitalopram</keyword>
  <keyword>Depression</keyword>
  <keyword>Dementia</keyword>
  <keyword>Treatment</keyword>
  <keyword>Depressive Syndrome in Alzheimer's Disease</keyword>
  <keyword>Depressive Syndrome in Vascular Dementia</keyword>
  <keyword>Depressive Syndrome in Mixed Vascular and Alzheimer's Dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Dementia, Vascular</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 19, 2009</submitted>
    <returned>August 26, 2009</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

